RTP Mobile Logo

B-raf Kinase Inhibitor GSK2118436 as Therapy for Patients with Metastatic Melanoma and Other Solid Tumors

CME test Downloadable PDF PowerPoint slides CME Information and Faculty Disclosures
Read Dr Love's original email (from July 6, 2010) Subscribe to Dr Love's email alerts
Slides from a presentation at ASCO 2010 and transcribed comments from a recent interview with Steven J O’Day, MD (6/25/10)
 

Kefford R et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Proc ASCO 2010;Abstract 8503.

Go to previous Journal Club